Molecular mechanisms of resistance: Free energy calculations of mutation effects on inhibitor binding to HIV‐1 protease

The changes in the inhibitor binding constants due to the mutation of isoleucine to valine at position 84 of HIV‐1 protease are calculated using molecular dynamics simulations. The calculations are done for three potent inhibitors‐KNI‐272, L‐735,524 (indinavir or MK‐639), and Ro 31‐8959 (saquinavir). The calculations agree with the experimental data both in terms of an overall trend and in the magnitude of the resulting free energy change. HIV‐1 protease is a homodimer, so each mutation causes two changes in the enzyme. The decrease in the binding free energy from each mutated side chain differs among the three inhibitors and correlates well with the size of the cavities induced in the protein interior near the mutated residue. The cavities are created as a result of a mutation to a smaller side chain, but the cavities are less than would be predicted from the wild‐type structures, indicating that there is significant relaxation to partially fill the cavities.

[1]  J N Weinstein,et al.  Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: a thermodynamic cycle-perturbation approach. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[3]  Arieh Ben-Naim,et al.  Solvation thermodynamics of nonionic solutes , 1984 .

[4]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[5]  J. Janin.  Angströms and calories. , 1997, Structure.

[6]  B Honig,et al.  Internal cavities and buried waters in globular proteins. , 1986, Biochemistry.

[7]  David A. Pearlman,et al.  A Comparison of Alternative Approaches to Free Energy Calculations , 1994 .

[8]  T. Bhat,et al.  Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. , 1995, Structure.

[9]  U. C. Singh,et al.  Free energy perturbation studies on inhibitor binding to HIV-1 proteinase , 1992 .

[10]  A. Wlodawer,et al.  The complexities of AIDS : an assessment of the HIV protease as a therapeutic target , 1991 .

[11]  J. Banavar,et al.  Computer Simulation of Liquids , 1988 .

[12]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[13]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[14]  J S Mills,et al.  Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. , 1997, Biochimica et biophysica acta.

[15]  B. Lee.  Estimation of the maximum change in stability of globular proteins upon mutation of a hydrophobic residue to another of smaller size , 1993, Protein science : a publication of the Protein Society.

[16]  B. Matthews,et al.  Structural and genetic analysis of protein stability. , 1993, Annual review of biochemistry.

[17]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[18]  B. Matthews,et al.  Similar hydrophobic replacements of Leu99 and Phe153 within the core of T4 lysozyme have different structural and thermodynamic consequences. , 1993, Journal of molecular biology.

[19]  D. Beveridge,et al.  Free energy via molecular simulation: applications to chemical and biomolecular systems. , 1989, Annual review of biophysics and biophysical chemistry.

[20]  D. Lamarre,et al.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.

[21]  L. M. Lehman,et al.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.

[22]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[23]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[24]  David A. Pearlman,et al.  Determining the contributions of constraints in free energy calculations: Development, characterization, and recommendations , 1993 .

[25]  A Tropsha,et al.  Application of free energy simulations to the binding of a transition-state-analogue inhibitor to HIV protease. , 1992, Protein engineering.

[26]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[27]  M. L. Connolly.  Solvent-accessible surfaces of proteins and nucleic acids. , 1983, Science.

[28]  J. Erickson,et al.  A quantum mechanical model of the hydration and acidity of the active site in aspartic proteases. , 1995, Advances in experimental medicine and biology.

[29]  R Langridge,et al.  Conic: a fast renderer for space-filling molecules with shadows. , 1991, Journal of molecular graphics.

[30]  T. Darden,et al.  The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .

[31]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[32]  Conrad C. Huang,et al.  The MIDAS display system , 1988 .

[33]  R Abagyan,et al.  Evaluating the energetics of empty cavities and internal mutations in proteins , 1997, Protein science : a publication of the Protein Society.

[34]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[35]  T. Yamazaki,et al.  Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. , 1996, Biochemistry.

[36]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[37]  P A Kollman,et al.  Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease. , 1991, Journal of medicinal chemistry.

[38]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.